This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Anecortave Acetate Versus Placebo in AMD Patients Following PDT

This study has been completed.
Information provided by:
Alcon Research Identifier:
First received: June 28, 2006
Last updated: August 4, 2008
Last verified: August 2008
The purpose of this study was to evaluate the efficacy of anecortave acetate for depot suspension (30 mg and 15 mg) plus PDT versus PDT alone with respect to maintenance of visual acuity in patients with wet AMD.

Condition Intervention Phase
AMD Drug: anecortave acetate Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Anecortave Acetate Versus Placebo in AMD Patients Following PDT

Further study details as provided by Alcon Research:

Primary Outcome Measures:
  • Mean change from the baseline in logMAR visual acuity score at Month 6

Secondary Outcome Measures:
  • % patients who maintained vision, number of months of angiographic evidence of needing PDT re-treatment, and mean lesion sizes for the total choroidal neovascularization (CNV) and the classic component to the total CNV.

Estimated Enrollment: 136
Study Start Date: May 2000
Study Completion Date: December 2001
Primary Completion Date: December 2001 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   50 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • AMD disease

Exclusion Criteria:

  • Age
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00346866

United States, Ohio
Beachwood, Ohio, United States, 44122
Sponsors and Collaborators
Alcon Research
Study Director: Patricia Zilliox Alcon Research
  More Information Identifier: NCT00346866     History of Changes
Other Study ID Numbers: C-00-07
Study First Received: June 28, 2006
Last Updated: August 4, 2008

Additional relevant MeSH terms:
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents processed this record on August 18, 2017